We previously established a trastuzumab-resistant breast cancer cell line (named BT-474-R) from the HER2-amplified cell line BT-474 and reported that YES1, a member of the Src family, plays an important role in acquired resistance to trastuzumab [7]. This evidence concerns the gene ERBB2 and breast carcinoma.